MedTrace Logo

Use of CereGate Therapy for Freezing of Gait in PD

NCT05292794 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-02-27

No results posted yet for this study

Summary

A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.

Conditions

  • Parkinson Disease
  • Freezing of Gait
  • Deep Brain Stimulation

Interventions

DEVICE

CereGate Software; BSN cDBS Programmer; BSN Burst Programmer

CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD: (i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced "cueing" stimulation-to mitigate FOG. The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System.

Sponsors & Collaborators

  • CereGate Inc.

    lead INDUSTRY

Principal Investigators

  • Brian Blischak · CereGate Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-18
Primary Completion
2027-06-30
Completion
2027-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05292794 on ClinicalTrials.gov